TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01514578
Drug: Dextrose in Water
Normalized name: dextrose in water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 1 hour duration
Study: NCT02236013
Drug: Gilteritinib
Normalized name: Gilteritinib
DrugBank: Gilteritinib (DB12141)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral
Study: NCT02236013
Drug: Idarubicin
Normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lyophilized powder administered intravenously
Study: NCT02236013
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: solution administered intravenously
Study: NCT02236013
Drug: Daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: solution administered intravenously
Study: NCT04226274
Drug: REN001
Normalized name: ReN001
DrugBank: ReN001 (DB05236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily for 12 weeks
Study: NCT04003142
Drug: Fezolinetant
Normalized name: Fezolinetant
DrugBank: Fezolinetant (DB15669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT03266653
Drug: cytotoxic t-lymphocytes
Normalized name: rabbit anti-human T-lymphocyte globulin Injection [Thymoglobulin]
DrugBank: Rabbit (DB10415)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBV specific CTLs will be generated from HLA related matched and mismatched donors in a GMP facility and administered to the patient with refractory CTLs.
Study: NCT03518060
Drug: JULUCA
Normalized name: Juluca
DrugBank: Rilpivirine (DB08864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: JULUCA is a combination of dolutegravir (INSTI) and rilpivirine (NNRTI).
Study: NCT02866331
Drug: G-CSF (Leucostim)
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02866331
Drug: Placebo (Normal saline)
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03376529
Drug: Ceftazidime
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.0 gram IV over 1 hour
Study: NCT03376529
Drug: Piperacillin/tazobactam
Normalized name: PIPERACILLIN/TAZOBACTAM
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4.5 grams IV over 1 hour
Study: NCT03376529
Drug: Aztreonam
Normalized name: Aztreonam
DrugBank: Aztreonam (DB00355)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.0 gram IV over 1 hour
Study: NCT00772525
Drug: Nerispirdine
Normalized name: Nerispirdine
DrugBank: Nerispirdine (DB12714)
Approvals — FDA: no, EMA: no, PMDA: no
Description: form: tablet~Route: oral
Study: NCT02308254
Drug: Lixisenatide
Normalized name: Lixisenatide
DrugBank: Lixisenatide (DB09265)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Abdominal administration
Study: NCT01635530
Drug: Ceftriaxone
Normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 g intravenous once a day, three weeks
Study: NCT00299715
Drug: Paliperidone extended-release
Normalized name: Paliperidone Extended-Release Tablets
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04103645
Drug: Vactosertib
Normalized name: Vactosertib
DrugBank: Vactosertib (DB15310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This drug is a TGF-Beta receptor type 1 inhibitor, by inhibiting phosphorylation of the ALK5 substrates SMAD2 and SMAD3. This inhibition could promote regeneration of normal human stem cells and proliferation of erythroid progenitors to treat the underlying hypoproliferative anemia in advanced MPNs.
Study: NCT03266627
Drug: cytotoxic t-lymphocytes
Normalized name: rabbit anti-human T-lymphocyte globulin Injection [Thymoglobulin]
DrugBank: Rabbit (DB10415)
Approvals — FDA: no, EMA: no, PMDA: no
Description: adenovirus specific cytotoxic t-lymphocytes will be collected and manufactured from HLA matched related or HLA mis-matched related donors and administered to eligible patients with refractory adenovirus or PID.
Study: NCT02137278
Drug: Vasoactive drug therapies
Normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue current vasoactive therapy
Study: NCT00298155
Drug: goserelin with dutasteride
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot) and begin dutasteride 3.5 mg qd; continue bicalutamide for one more week.
Study: NCT00298155
Drug: goserelin with bicalutamide and dutasteride
Normalized name: tamsulosin and dutasteride
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot) and begin dutasteride 3.5 mg qd.
Study: NCT00298155
Drug: goserelin with bicalutamide and dutasteride and ketoconazole
Normalized name: tamsulosin and dutasteride
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot), begin dutasteride 3.5 mg qd and ketoconazole 200 mg tid (with hydrocortisone 30 mg).
Study: NCT01603251
Drug: Artemether-lumefantrine combination + single dose Ivermectin
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Artemether-lumefantrine (AL) combination + Ivermectin (200ug/kg) given once together with the first dose of AL. A placebo is given together with the fifth dose of AL.
Study: NCT01603251
Drug: Artemether-lumefantrine combination + repeated dose Ivermectin
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Artemether-lumefantrine (AL) combination + Ivermectin (200ug/kg) given together with the first and fifth dose of AL.
Study: NCT01852214
Drug: Prasugrel
Normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients receiving prasugrel will be treated with 60mg loading dose and 10mg maintenance dose
Study: NCT01852214
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receiving ticagrelor will be treated with a 180mg loading dose and 90mg bid maintenance dose
Study: NCT00005880
Drug: budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02465801
Drug: GCSF
Normalized name: GlycoPEG-GCSF
DrugBank: GlycoPEG-GCSF (DB06022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GCSF 5 mcg/kg/day
Study: NCT00795756
Drug: liposome-encapsulated cytarabine (DepoCyte)
Normalized name: cytarabine liposome Injection [DepoCyt]
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DepoCyte 50 mg injected intrathecally x6-8 (6: B-lineage, 8: T-lineage) during induction/consolidation phases
Study: NCT01408914
Drug: Higher-Dose Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention phase of this trial will last 8 weeks. During that time, subjects will receive the following companion drugs: isoniazid (INH, 5 mg/kg/day), ethambutol (EMB, 20 mg/kg/day), and pyrazinamide (PZA, 25 mg/kg/day), pyridoxine (50 mg), the standard doses used in treatment. Subjects will also be randomized to receive one of the following weight-based doses of the study drug, rifampin (RIF): 10 mg/kg/day (standard dose, control), 15 mg/kg/day (intervention 1), 20 mg/kg/day (intervention 2). All patients will receive at least standard dose of RIF, the efficacy of which in multidrug-treatment for TB is well established. Placebo will be used to control only the additional RIF capsules provided in the intervention arms.
Study: NCT01928329
Drug: Exenatide (Bydureon®)
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02029950
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02029950
Drug: Daunorubicin Hydrochloride
Normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02029950
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02029950
Drug: Idarubicin Hydrochloride
Normalized name: Idarubicin Hydrochloride
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02029950
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT00697203
Drug: Dalcetrapib
Normalized name: Dalcetrapib
DrugBank: Dalcetrapib (DB12181)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg po daily for 12 weeks
Study: NCT00697203
Drug: Dalcetrapib
Normalized name: Dalcetrapib
DrugBank: Dalcetrapib (DB12181)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600mg po daily for 12 weeks
Study: NCT00697203
Drug: Dalcetrapib
Normalized name: Dalcetrapib
DrugBank: Dalcetrapib (DB12181)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900mg po daily for 12 weeks
Study: NCT00047580
Drug: tizanidine hydrochloride capsule
Normalized name: Tizanidine Hydrochloride
DrugBank: Tizanidine (DB00697)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03390686
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15 mg/kg IV every 3 weeks on Day 1
Study: NCT03390686
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles
Study: NCT03390686
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles
Study: NCT00000354
Drug: Lofexidine
Normalized name: LOFEXIDINE
DrugBank: Lofexidine (DB04948)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03523754
Drug: Isosorbide Mononitrate 40 MG to study group
Normalized name: isosorbide mononitrate 40 MG
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide Mononitrate will be added to Misoprostol, to determine their combined effect on cervical ripening \& induction of labor in study group
Study: NCT00385515
Drug: SNX-1012 (meclocycline sulfosalicylate)
Normalized name: Meclocycline Sulfosalicylate
DrugBank: Meclocycline (DB13092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablets to be dissolved in water for oral swish and expectorate; 30 mg, 4 times daily for 10 days
Study: NCT00071994
Drug: gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT01529840
Drug: somatropin
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Retrospective data collection based on data obtained from a prospective, open-label, randomised, parallel-group trial (S/GHD/004/NOO) combined with a present follow-up visit
Study: NCT05283057
Drug: Empagliflozin 25 MG
Normalized name: empagliflozin 25 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: single dose of the SGLT inhibitor Empagliflozin was given
Study: NCT01748643
Drug: deep neuromuscular blockade with rocuronium, reversal with sugammadex
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: after induction of anesthesia, a rocuronium infusion (0.6mg/kg (lean body mass)/h,) is started and titrated to a post tetanic count of 1-2 twitches. At the end of surgery neuromuscular blockade will be reversed with sugammadex 4mg/kg. Patients are extubated when TOF ratio \> 0.9.
Study: NCT01748643
Drug: normal neuromuscular blockade reversal with rocuronium, reversal with neostigmine
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After induction of anesthesia, top-ups of rocuronium (10mg) are given as needed to maintain a train of four count of 1-2. At the end of surgery neuromuscular blockade will be reversed with neostigmine 50μg/kg and glycopyrrolate 10μg/kg (lean body mass). Patients are extubated when the train of four ratio is \> 0.9.
Study: NCT03533179
Drug: Glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon 1 mg/ml solution is dissolved in 50 ml isotonic fluid and injected as bolus corresponding to 50 micrograms/kg over 1-3 minutes from time=0 on day C+E. on day D (glucagon 2), 50 micrograms/kg of glucagon is infused over 30 minutes from time=0 to time =30.
Study: NCT03533179
Drug: Esmolol
Normalized name: Esmolol
DrugBank: Esmolol (DB00187)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esmolol hydrochloride 10 mg/ml is infused from time -15 min to time + 30 minutes as an initial bolus followed by an infusion. infusion rate is tapered if heart rate declines below 30 beats per minute (bpm) or \>25 % from baseline, systolic blood pressure decreases below 80 mmHg or the participant experiences side effects.
Study: NCT03533179
Drug: Physiologic saline - glucagon dummy
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Isotonic 0.9 % sodium chloride solution is administered as matching placebo to glucagon, and injected in identical rates on corresponding days.
Study: NCT03533179
Drug: Physiologic saline - esmolol dummy
DrugBank: Esmolol (DB00187)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotonic 0.9 % sodium chloride solution is administered as matching placebo to esmolol, and injected in identical rates on corresponding days.
Study: NCT03254927
Drug: CDX-3379 and cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose: 12 mg/kg CDX-3379 once every 3 weeks in combination with 400 mg/m2 cetuximab on the first day followed by weekly doses of 250 mg/m2 cetuximab.
Study: NCT00909389
Drug: Vytorin (R) (Ezetimibe + Simvastatin)
Normalized name: ezetimibe / simvastatin Oral Tablet [Vytorin]
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vytorin (R) (Ezetimibe + Simvastatin) 1 tablet once daily to be taken by mouth in the evening for 28 days
Study: NCT02184689
Drug: fexinidazole
Normalized name: fexinidazole
DrugBank: Fexinidazole (DB12265)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01673451
Drug: E2006
Normalized name: Elafibranor
DrugBank: Elafibranor (DB05187)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: 2.5 mg, 5 mg, 10 mg, 25 mg, 50 mg, and 75 mg E2006 administered as capsules
Study: NCT01516424
Drug: Blonanserin
Normalized name: Blonanserin
DrugBank: Blonanserin (DB09223)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Blonanserin tablets: 8 - 24mg/day; twice daily after breakfast and dinner; in the meantime, the placebo and positive drug were taken in whole tablets. When the morning and evening doses could not be administered equally, the evening dose should be greater than the morning dose. The interval between 2 dose escalations should not be shorter than 3 days.
Study: NCT01516424
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone tablets: 2 - 6mg/day; twice daily after breakfast and dinner; in the meantime, the placebo and positive drug were taken in whole tablets. When the morning and evening doses could not be administered equally, the evening dose should be greater than the morning dose. The interval between 2 dose escalations should not be shorter than 3 days.
Study: NCT03350633
Drug: Tocilizumab Injection
Normalized name: tocilizumab Injection
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab Injection will be intravenously administered with a dose of 8 mg/kg every 4 weeks.
Study: NCT02389738
Drug: Regadenoson
Normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regadenoson administration on post-op day 2 after temozolomide administration. Temozolomide plasma and dialysate concentrations will be obtained over 18 hours post temozolomde administration.
Study: NCT01333059
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05451147
Drug: Metformin Hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drug: Metformin Form: Tablet Dose: 500mg BID/TDS, Before meals Mode of Administration: Oral Anupaan: Plain water Duration: 3 Months
Study: NCT02389738
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide administration on post-op day 1 and 2. Temozolomide plasma and dialysate concentrations will be obtained over 18 hours post temozolomde administration.
Study: NCT01683955
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical tranexamic acid (2g/100mL 0.9% saline)
Study: NCT00991055
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A total 16-week randomized, double-blind, controlled study to compare the efficacy and safety of pioglitazone 15mg once daily added to combination metformin plus sulfonylurea with those of placebo combining control group.~(4-week run in period and 12-week pioglitazone 15mg added to combination therapy of sulfonylurea plus metformin and placebo control group in patients with type 2 diabetes)
Study: NCT00278083
Drug: Study drug administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01133301
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/d Naltrexone will be administrated during three weeks.
Study: NCT01914744
Drug: Entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: entecavir 0.5 mg/day PO
Study: NCT01914744
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: lamivudine 100 mg/day PO
Study: NCT00240253
Drug: pramlintide acetate
Normalized name: Pramlintide Acetate
DrugBank: Pramlintide (DB01278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clear, colorless, sterile solution for SC injection
Study: NCT01019642
Drug: cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4,000 IU per day during 6 months. Capsule form.
Study: NCT00237627
Drug: PS-341
Normalized name: PS
DrugBank: Phosphatidyl serine (DB00144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PS-341 will be administered as an intravenous push into a side arm of either a peripheral or central intravenous line infusing normal saline at 100 ml/hr. Patients will be treated twice weekly for two weeks, followed by a one week rest period, such that the typical days of treatment will be days 1, 4, 8, 11 of each three-week cycle. The initial dose level for PS-341 will be 0.9 mg/m2/dose intravenously, while subsequent dose levels will be determined according to a modified Fibonacci schema
Study: NCT00237627
Drug: Doxil
Normalized name: Doxil
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxil will be administered at a dose of 30 mg/m2 as a 1 hour infusion through either a peripheral or central intravenous line every 3 weeks (on day 4 of each 21 day cycle)
Study: NCT00237627
Drug: Velcade
Normalized name: Velcade
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Velcade will be adminstered intravenously at 1.3 mg/m2 days 1, 4, 8, 11 every 3 weeks
Study: NCT00004323
Drug: anti-thymocyte globulin
Normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00004323
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00004323
Drug: mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004323
Drug: methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00130390
Drug: Nitazoxanide
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One nitazoxanide 500 mg tablet twice daily for 28 days
Study: NCT02788292
Drug: Acetylcysteine
Normalized name: Acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See arm description
Study: NCT00912509
Drug: riboflavin
Normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: riboflavin 0.1% is applied every 2 minutes for 30 minutes
Study: NCT00204581
Drug: Interleukin-2 (Proleukin)
Normalized name: Interleukin-2 aldesleukin
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-12 MIE/d 3times a week
Study: NCT00595075
Drug: Ramelteon
Normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramelteon 8 mg tablet by mouth x 1 dose
Study: NCT02518698
Drug: Radium-223 dichloride (Xofigo, BAY88-8223)
DrugBank: Radium Ra 223 dichloride (DB08913)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Therapies used to treat prostate cancer and more specifically castrate resistant prostate cancer inclusively Xofigo (Radium-223 dichloride, BAY88-8223)
Study: NCT04577703
Drug: CT053PTSA
Normalized name: Ct053ptsa free base
DrugBank: Ningetinib (DB16256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT053PTSA will be administered daily in fasting state
Study: NCT01397591
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given intravenously
Study: NCT03403790
Drug: Quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral (extended-release tablet)
Study: NCT00338000
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03719300
Drug: inodiftagene vixteplasmid
Normalized name: Inodiftagene vixteplasmid
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BC-819 at 20 mg/50 mL, instilled intravesically into the bladder, with a retention time of at least 30 minutes (up to 2 hours).~Induction Phase (weekly treatments): 10 weekly treatments; Maintenance Phase: treatment every 3 weeks for up to 84 additional weeks
Study: NCT02800746
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose 15 mg/kg mg is intravenously administered on 7-10 day before surgery.
Study: NCT01946646
Drug: S-1-CCRT
Normalized name: menthol 1 MG [Luden's]
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no